

## **Medical Properties Trust**

MPT Operating Partnership, L.P. MPT Finance Corporation

## 6.375% Senior Notes due 2024

This Supplement is qualified in its entirety by reference to the Preliminary Prospectus Supplement and the accompanying Prospectus (as supplemented through and including the date hereof, the "<u>Preliminary Prospectus Supplement</u>"). The information in this Supplement supplements the Preliminary Prospectus Supplement and updates and supersedes the information in the Preliminary Prospectus Supplement to the extent it is inconsistent with the information in the Preliminary Prospectus Supplement. Terms used herein but not defined herein shall have the respective meanings as set forth in the Preliminary Prospectus Supplement.

Other information presented in the Preliminary Prospectus Supplement is deemed to have changed to the extent affected by the changes described herein.

**Issuers:** MPT Operating Partnership, L.P. and MPT Finance Corporation

**Guarantee:** Guaranteed by the Issuers' parent company, Medical Properties Trust, Inc.

Aggregate Principal Amount: \$500,000,000

**Title of Securities:** 6.375% Senior Notes due 2024

Final Maturity Date:March 1, 2024Public Offering Price:100.000%Coupon:6.375%Yield to Maturity:6.375%

**Spread to Benchmark:** +470 bps

**Benchmark Treasury:** UST 2.75% due February 15, 2024

Gross Proceeds to Issuers: \$500,000,000

Net Proceeds to Issuers before Expenses: \$493,125,000

**Interest Payment Dates:** March 1 and September 1

**Record Dates:** February 15 and August 15

**First Interest Payment Date:** September 1, 2016

**Optional Redemption:** Make-whole call at T+50 bps until March 1, 2019.

> From and after March 1, 2019, at the prices set forth below (expressed as percentages of the principal amount), plus accrued and unpaid interest to, but not including, the redemption date, if redeemed

during the 12-month period beginning on March 1 of each of the years indicated below:

2019 104.781% 2020 103.188% 2021 101.594% 2022 and thereafter 100.000%

**Optional Redemption with Equity Proceeds:** Prior to March 1, 2019, up to 35% of the notes at a redemption price equal to 106.375% of the

aggregate principal amount thereof, plus accrued and unpaid interest thereon to, but not including the

redemption date.

**Change of Control:** Putable to the Issuers at 101% of principal, plus accrued and unpaid interest, if any, thereon to, but not

including, the change of control purchase date.

CUSIP: 55342U AF1 ISIN: US55342UAF12

**Distribution:** SEC Registered (Registration No. 333-190543)

Listing: None

**CUSIP/ISIN Numbers:** 

**Trade Date:** February 17, 2016

**Settlement:** T+3 on February 22, 2016

**Use of Proceeds:** As set forth in the Preliminary Prospectus Supplement

**Active Joint Book-Running Managers:** Merrill Lynch, Pierce, Fenner & Smith

> Incorporated Barclays Capital Inc.

Wells Fargo Securities, LLC

**Passive Joint Book-Running Managers:** Goldman, Sachs & Co.

> J.P. Morgan Securities LLC KeyBanc Capital Markets Inc.

**Lead Managers:**BBVA Securities Inc.

Credit Agricole Securities (USA) Inc. Credit Suisse Securities (USA) LLC Deutsche Bank Securities Inc. Mitsubishi UFJ Securities (USA), Inc. RBC Capital Markets. LLC

Stifel, Nicolaus & Company, Incorporated

Stifel, Nicolaus & Company, Incorporated SunTrust Robinson Humphrey, Inc.

**Denominations/Multiple:** 

\$2,000 and integral multiples of \$1,000 in excess thereof

The Issuers have filed a registration statement (including the Preliminary Prospectus Supplement) with the SEC for the offering to which this communication relates. Before you invest, you should read the Preliminary Prospectus Supplement in that registration statement and other documents MPT Operating Partnership, L.P. and Medical Properties Trust, Inc. have filed with the SEC that are incorporated by reference in the Preliminary Prospectus Supplement for more complete information about the Issuers, the Guarantor and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies may be obtained from BofA Merrill Lynch at (800) 294-1322 or e-mail: dg.prospectus\_requests@baml.com, Barclays Capital at (888) 603-5847 or e-mail: barclaysprospectus@broadridge.com or Wells Fargo Securities at (800) 645-3751 or e-mail: wfscustomerservice@wellsfargo.com.

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.